SCHEMBL24288441

SCHEMBL24288441

CCCCCCCCCN(CCCO)C(=O)C(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HSD17B10 Q99714 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TSHR P16473 1/20 0.43
CA12 O43570 3/20 0.41
CA1 P00915 3/20 0.41
CA9 Q16790 3/20 0.41
CA2 P00918 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.39
ZDHHC20 Q5W0Z9 2/20 0.38
ZDHHC2 Q9UIJ5 1/20 0.38
MGLL Q99685 1/20 0.38
MMP1 P03956 1/20 0.36
MMP2 P08253 1/20 0.36
MMP3 P08254 1/20 0.36
MMP8 P22894 1/20 0.36
DNM1 Q05193 2/20 0.35
CES2 O00748 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20349287 1.00 LMNA (0.43) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL20349290 0.93 CA12 (0.41) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL24288442 0.93 CA12 (0.41) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL25634909 0.92 CA12 (0.45) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL11704187 0.92 CA12 (0.47) ALDH1A1HSD17B10MEN1KMT2ATSHR
SCHEMBL20349292 0.92 CA12 (0.47) ALDH1A1HSD17B10MEN1KMT2ATSHR
SCHEMBL13223502 0.91 CA12 (0.39) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL23031982 0.90 CA12 (0.45) ALDH1A1CA12CA1CA9CA2
SCHEMBL9179561 0.88 MEN1 (0.35) MEN1KMT2ACA12CA1CA9
SCHEMBL20349285 0.87 MEN1 (0.43) LMNAALDH1A1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820728-B2 Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids Acuitas Therapeutics, Inc. (CA) 2023-11-21 US disclosed
US-11820728-B2 Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids Acuitas Therapeutics, Inc. (CA) 2023-11-21 US disclosed
US-20220081392-A1 NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS Acuitas Therapeutics, Inc. (CA) 2022-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11820728-B2 Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids TTPA, ACAA2, CPT2 LMNA 12/4885ALDH1A1 207/4885HSD17B10 547/4885
US-20220081392-A1 NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS TTPA, ACAA2, POLRMT LMNA 20/4885ALDH1A1 388/4885HSD17B10 615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.